Compare Marathon Petroleum Corp (MPC) vs Moderna, Inc. (MRNA) Price & Performance

Marathon Petroleum (MPC) trades at $442.26, up 2.29% with strong technical momentum and bullish moving average signals. The stock shows robust fundamentals with a P/E of 15.33, ROE of 47.9%, and consistent earnings beats in recent quarters. Recent news highlights refining margin strength amid tight global capacity, though potential diesel export restrictions pose headwinds. Technical indicators show the stock trading near pivot point resistance at $442 with RSI suggesting potential overbought conditions.

MPC presents a compelling value opportunity with attractive valuation metrics and strong profitability, though investors face risks from potential regulatory changes and volatile energy markets. Analyst consensus remains strongly bullish with 76% buy ratings and a $420.30 price target, suggesting modest downside from current levels. The company's solid cash flow generation and dividend payments provide shareholder returns support.

Moderna (MRNA) trades at $196.48, up 4.81% amid Nasdaq-100 inclusion news, though it remains well below the analyst consensus target of $115.70. The stock shows bullish technical momentum with recent earnings beats, but faces fundamental challenges with negative profit margins and declining revenue from pandemic-era highs. The company's cash flow improved in 2025, turning positive for the first time since 2022, while its pipeline, including oncology vaccines, attracts investor interest despite valuation concerns.

Outlook: Near-term momentum from index fund buying and pipeline updates may support the stock, but high valuation multiples and persistent losses pose significant risks. Long-term growth depends on successful commercialization of non-COVID products, with current prices reflecting optimistic scenarios. Investors should weigh the potential of the mRNA platform against execution risks and competitive pressures.